Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis

JAMA. 2006 Nov 8;296(18):2201-2; author reply 2203-4. doi: 10.1001/jama.296.18.2201-b.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Rheumatoid / drug therapy*
  • Humans
  • Immunologic Factors / adverse effects*
  • Infliximab
  • Risk
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunologic Factors
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab